← All candidates
Nine insider buys in the last year — $13.12M in all.
63 filings on record.
ARTVArtiva Biotherapeutics, Inc.
NasdaqGM · Healthcare · $420.46M
$8.60
-3.48% today
Nine insider buys in the last year — $13.12M in all.
Nothing in the last fortnight.
Price · 1Y · daily● 9 buys● 10 sells◆ 4 8-K
▸ hover a marker for the filing · drag to zoom · daily bars sharpen to 30-min on close ranges · 4 moves explained
AI brief · from the filings on this pagePro
The filings, the score and the setup on this page, read for you in about ten seconds — what the insiders did, and what stands against it.
Market cap
$420.46M
Float
19.6M
40% public
Short % float
Pro
The buyers
▸ each insider's past open-market buys, measured ~6 months (120 trading days) later, against the S&P over the same spans · split-adjusted · pre-scheduled 10b5-1 plan trades excluded · past outcomes, not predictions
10% owner
Ra Capital Management, L.p.
Bought $4.34M on Jun 11 — 548,580 sh @ $7.91, held indirect, 3.4% of their stake.
4 of 8 positions beat the S&P
Institutional stakes
▸ a holder crossing 5% files Schedule 13D if they intend to act on the company, 13G if they certify they will not · /A amends an earlier filing
16 filingsnewest first
The record
newest first
DateTypeInsiderOf stakeShares @ priceValue
51 more transactions on Pro →Context
Wall St
$35.80 avg target
+316.3% vs today · 5 analysts
▸ relayed analyst opinion, which tends to run optimistic — not our forecast or advice
Earnings · EPS vs forecast
0 of 4 quarters beat
Q1 '26−$0.95 act−$0.11
Q4 '25−$0.84 act−$0.04
Q3 '25−$0.88 act−$0.08
Q2 '25−$0.87 act−$0.10
Coverage
Is Artiva Biotherapeutics (NASDAQ:ARTV) In A Good Position To Deliver On Growth Plans?Simply Wall St. · 04-17Artiva Biotherapeutics Spotlights RA as Lead NK Cell Program, Eyes H1 Efficacy Data Catalyst at NeedhamMarketBeat · 04-15Artiva Biotherapeutics Pivots to Rheumatoid Arthritis at TD Cowen, Teases 2026 RA Data UpdateMarketBeat · 03-04
The file stays open
63 filings on record.
The next one will be too.
▸ SEC EDGAR · FINRA · Nasdaq — public sources only · research, not advice